We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Vivus

News List

Vivus amends agreement with Nordmark for Pancreaze capsules pharmaceutical-technology
July 01, 2019
Vivus has amended its manufacturing and supply agreement with Nordmark Arzneimittel for Pancreaze (pancrelipase) delayed-release capsules covering an initial term of ten years.
VIVUS Announces Marketing Approval of Avanafil in the Russian Federation for the Treatment of Erectile Dysfunction firstwordpharma
March 15, 2019
VIVUS, Inc. (NASDAQ: VVUS; the "Company"), a biopharmaceutical company, today announced that the Ministry of Health of the Russian Federation has approved 50 mg, 100 mg and 200 mg tablets of avanafil for the treatment of erectile dysfunction (ED).